Technology
Health
Biotechnology

Merrimack Pharmaceuticals

$6.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-6.30%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MACK and other stocks, options, ETFs, and crypto commission-free!

About

Merrimack Pharmaceuticals, Inc. Common Stock, also called Merrimack Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Read More Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Employees
27
Headquarters
Cambridge, Massachusetts
Founded
1993
Market Cap
95.27M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
124.27K
High Today
$7.11
Low Today
$6.28
Open Price
$7.11
Volume
31.37K
52 Week High
$10.53
52 Week Low
$3.34

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Cancer Prevention
Pharmaceutical

News

Yahoo FinanceMar 7

Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4

Merrimack Pharmaceuticals, Inc. MACK incurred a loss of 97 cents per share for the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of $1.01 per share but wider than the year-ago quarter’s loss of 89 cents. Merrimack sold its only marketed product, Onivyde, to Ipsen in 2017. As a result, the company could not generate any revenues in the reported quarter in want of a marketed product in its portfolio. Shares of Merrimack were almost 6.5% up following its release of fourth-quart...

49
PR NewswireMar 6

Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results

CAMBRIDGE, Mass., March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018. "Last quarter, we engaged external advisors and initiated a process to explore Merrimack's strategic alternatives. This is an active process that we are working expeditiously to bring to conclusion, with a range of potential outcom...

28

Earnings

-$1.88
-$1.30
-$0.72
-$0.14
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.